1. Home
  2. PCSA vs SYNX Comparison

PCSA vs SYNX Comparison

Compare PCSA & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.79

Market Cap

8.2M

Sector

Health Care

ML Signal

HOLD

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.26

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
SYNX
Founded
2011
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
7.3M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
PCSA
SYNX
Price
$2.79
$1.26
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
56.2K
135.3K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,000.00
N/A
Revenue This Year
N/A
$32.35
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.73
52 Week High
$8.88
$2.15

Technical Indicators

Market Signals
Indicator
PCSA
SYNX
Relative Strength Index (RSI) 50.93 63.60
Support Level $1.96 $0.93
Resistance Level $3.26 $1.31
Average True Range (ATR) 0.36 0.08
MACD 0.00 0.04
Stochastic Oscillator 31.78 77.25

Price Performance

Historical Comparison
PCSA
SYNX

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: